Zimbabwe has declined a major US health deal valued at 367 million US dollars (272 million pounds) over five years over the United States' request for sensitive biological samples.
The decision came to light following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesperson has since stated that the United States was requesting health data for research and commercial gain while was unwilling to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for more negotiations to reach a deal agreeable to all parties so the country's critical HIV programme can proceed.
Broader Context
This development comes after a similar case in Kenya, where a high court halted a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance transparency and responsibility.
As per statements, 16 African countries have so far agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the resulting innovations would be available to our population should a future health crisis arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting structures already established through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This framework is intended to guarantee that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration could be arranged in a way that honours the sovereignty and interests of both nations."
Health Experts Response
Medical experts expressed it understood the government's concerns, but recommended that talks should continue since much of the nation's HIV programmes relied on foreign aid.
"In cases where technical issues arise, such as those relating to information security or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," it said.
The situation highlights the continuing challenges between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.